SEED Therapeutics Initiates Phase 1a Study of ST-01156, Targeting Advanced Solid Tumors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Clinical Trial Launch: SEED Therapeutics has dosed the first patient in its Phase 1a study of ST-01156, targeting advanced solid tumors dependent on RBM39, marking a significant milestone for patients urgently needing new therapeutic options.
- Drug Design Advantage: ST-01156 is an orally administered molecular glue degrader designed to selectively degrade RBM39, a key regulator essential for the survival of various cancers, with preclinical studies demonstrating complete tumor regression in Ewing sarcoma and KRAS-mutant colorectal cancer models.
- FDA Designation Support: The drug has received U.S. FDA Orphan Drug and Rare Pediatric Disease Designations specifically for Ewing sarcoma, highlighting its market potential given that no new therapeutic agents have been approved in the last 30 years.
- Innovative Study Design: The trial involves administering ST-01156 orally once daily for 28 consecutive days, aiming to evaluate its safety and tolerability while integrating pharmacokinetics and biomarker learning to optimize future therapeutic development.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like SEED with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on SEED
About SEED
Origin Agritech Ltd is a holding company mainly engaged in agricultural biotechnology. The Company specializes in crop seed breeding and genetic improvement, seed production, processing, distribution and related technical services. The Company and its subsidiaries are primarily engaged in corn seed development and distribution business as well as research on crop genetic improvement breeding technology. The Company's products include corn seeds, nutritionally enhanced corn (NEC), soybean seeds, rapeseed seeds and rice seeds. The Company has a breeding research platform in the country, including research centers, breeding stations, winter breeding bases, and others. The Company mainly conducts its business in domestic and overseas markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Origin Agritech to Announce FY2025 Financial Results on January 30
- Financial Results Announcement: Origin Agritech will release its fiscal year 2025 financial results on January 30, 2026, reflecting the company's ongoing commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call on February 2, 2026, at 8 a.m. ET, led by CEO Weibin Yan and CFO Patrick Cheng, aimed at providing in-depth discussions on financial results and business updates with investors.
- Investor Engagement: Investors can submit questions via email by January 29, demonstrating the company's emphasis on investor feedback and enhancing investor relations.
- Technological Innovation Background: Since its founding in 1997, Origin Agritech has made significant strides in crop seed biotechnology, being the first to receive a Bio-Safety Certificate for transgenic corn from China's Ministry of Agriculture, showcasing its leadership in the industry.
Continue Reading
Origin Agritech to Announce FY 2025 Financial Results
- Earnings Announcement Schedule: Origin Agritech is set to release its FY 2025 financial results on January 30, 2026, and will discuss these results in a conference call on February 2, which may influence the company's stock price.
- Conference Participation Details: The call will be led by CEO Weibin Yan and CFO Patrick Cheng, allowing investors to submit questions via email by January 29, enhancing engagement with the investment community.
- Technological Innovation Background: Founded in 1997, Origin Agritech has made significant strides in crop seed biotechnology, with its phytase corn being the first transgenic corn to receive a Bio-Safety Certificate from China's Ministry of Agriculture, showcasing the company's leadership in the industry.
- Future Outlook Statements: The company's forward-looking statements highlight uncertainties regarding future business and financial performance, urging investors to consider market changes and potential risks, thereby ensuring transparency and compliance.
Continue Reading